Health Trials

About this trial

A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)

Eligibility criteria

Qualifiers

Willingness to comply with study procedures/requirements

Capable of giving informed consent

Diagnosis of at least one PG ulcer by clinical, histological and laboratory assessments with a minimum wound size of 4 cm2.

Undergoing at least once a week standard of care wound care at home or at a wound care facility

Disqualifiers

Has previously received at any time any therapeutic agent directly targeted to IL-23 including, but not limited to, guselkumab, risankizumab, tildrakuzumab, or mirikizumab

12 weeks for ustekinumab, ixekizumab, secukinumab, brodalumab;

8 weeks for infliximab;

6 weeks for adalimumab;

Trial design

Treatments tested in this trial

  • Guselkumab

Treatment groups

17 Participants
are divided into 1 treatment group

Locations

2
Ohio State Dermatology43215, ColumbusOhio, United States
Oregon Health and Science University97239, PortlandOregon, United States

Sponsors and collaborators

Oregon Health and Science University

Lead sponsor

Janssen Scientific Affairs, LLC

Collaborator

Ohio State University

Collaborator

Source ClinicalTrials.gov